Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 20/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 20/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 19/20 | 1.00 |
| ▸ | KDR | P35968 | 17/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.73 |
| ▸ | DRD3 | P35462 | 1/20 | 0.73 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.73 |
| ▸ | ETV6 | P41212 | 1/20 | 0.73 |
| ▸ | HTR2B | P41595 | 1/20 | 0.73 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14905336 | 0.94 | FGFR1 (1.00) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL14905562 | 0.90 | FGFR1 (1.00) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL14905312 | 0.90 | FGFR1 (1.00) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL14905541 | 0.88 | FGFR1 (1.00) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL20808264 | 0.87 | FGFR3 (0.84) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL16523110 | 0.87 | FGFR3 (0.84) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL14906703 | 0.87 | FGFR1 (0.78) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL14905449 | 0.87 | FGFR3 (1.00) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL14905218 | 0.86 | FGFR1 (1.00) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL14905531 | 0.86 | FGFR4 (1.00) | FGFR1FGFR2FGFR3FGFR4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203011-A1 | BI-Heteroaryl Substitute 1,4-Benzodiazepines And Uses Thereof For The Treatment Of Cancer | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203011-A1 | BI-Heteroaryl Substitute 1,4-Benzodiazepines And Uses Thereof For The Treatment Of Cancer | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-11542247-B2 | Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2023-01-03 | — | — | US | disclosed |
| EP-3353164-B1 | BI-HETEROARYL SUBSTITUTED 1,4-BENZODIAZEPINES AND USES THEREOF FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20200255401-A1 | NEW COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-13 | — | — | US | disclosed |
| EP-2776436-B1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2019-03-13 | — | — | EP | disclosed |
| US-9757364-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2017-09-12 | — | — | US | disclosed |
| US-9757364-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2017-09-12 | — | — | US | disclosed |
| US-20170105978-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-04-20 | — | — | US | disclosed |
| US-20170105978-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-04-20 | — | — | US | disclosed |
| WO-2017050865-A1 | BI-HETEROARYL SUBSTITUTED 1,4-BENZODIAZEPINES AND USES THEREOF FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-30 | — | — | WO | disclosed |
| US-9527844-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-12-27 | — | — | US | disclosed |
| US-9527844-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-12-27 | — | — | US | disclosed |
| US-20160108034-A1 | NAPHTHYRIDINE DERIVATIVE COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-04-21 | — | — | US | disclosed |
| US-9309241-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| US-9309241-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| US-20150057293-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| US-20150057293-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| WO-2013061077-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057293-A1 | NEW COMPOUNDS | NQO1, NTPCR, NDC1 | FGFR1 2337/4885FGFR2 2426/4885FGFR3 2292/4885 |
| US-20170105978-A1 | NEW COMPOUNDS | NQO1, NTPCR, NDC1 | FGFR1 2337/4885FGFR2 2426/4885FGFR3 2292/4885 |
| US-20160108034-A1 | NAPHTHYRIDINE DERIVATIVE COMPOUNDS | NQO1, NDC1, NTPCR | FGFR1 1630/4885FGFR2 1858/4885FGFR3 2257/4885 |
| US-20200255401-A1 | NEW COMPOUNDS | NQO2, NQO1, NDUFS5 | FGFR1 2808/4885FGFR2 3541/4885FGFR3 3347/4885 |
| US-20230203011-A1 | BI-Heteroaryl Substitute 1,4-Benzodiazepines And Uses Thereof For The Treatment Of Cancer | GABBR1, GABRA5, GABRA4 | FGFR1 2124/4885FGFR2 1594/4885FGFR3 1030/4885 |
| US-11542247-B2 | Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer | GABBR1, GABRA5, GABRA4 | FGFR1 2124/4885FGFR2 1594/4885FGFR3 1030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.